Valuation : GlaxoSmithKline Pakistan Limited

Market Cap 107B 385M 331M 311M 284M 533M 36.65B 538M 3.66B 1.43B 18.57B 1.44B 1.41B 61.54B P/E 2026 *
10.1x
P/E 2027 * 8.38x
Enterprise Value 107B 385M 331M 311M 284M 533M 36.65B 538M 3.66B 1.43B 18.57B 1.44B 1.41B 61.54B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.43x
Free-Float
16.89%
Yield 2026 *
5.39%
Yield 2027 * 6.21%
Aug. 28 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
Aug. 25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 25 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
May. 31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
Apr. 27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
Apr. 06 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
1 day-1.12%
1 week-3.18%
Current month-3.09%
1 month-3.01%
3 months-5.58%
6 months-0.12%
Current year-14.06%
1 week 333.7
Extreme 333.7
346.45
1 month 333.7
Extreme 333.7
356
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2011-05-06
Director/Board Member - 2018-12-04
Director/Board Member 72 2020-04-01
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-3.18%-18.18%+383.01% 389M
-1.52%-7.86%+57.90%+111.09% 1,047B
-0.82%-1.62%+50.05%+62.37% 646B
+0.37%-3.22%+21.87%+72.88% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.59%-3.15%+49.83%+67.70% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.45%-0.27%+29.84%+91.34% 181B
Average -0.48%-2.59%+22.99%+81.94% 365.97B
Weighted average by Cap. -0.12%-3.46%+36.90%+64.92%

Financials

2026 *2027 *
Net sales 68.81B 248M 214M 201M 183M 344M 23.64B 347M 2.36B 924M 11.98B 932M 912M 39.7B 74.58B 269M 231M 217M 198M 373M 25.62B 376M 2.56B 1B 12.98B 1.01B 988M 43.02B
Net income 10.49B 37.84M 32.56M 30.57M 27.91M 52.42M 3.6B 52.86M 360M 141M 1.83B 142M 139M 6.05B 12.42B 44.8M 38.55M 36.19M 33.05M 62.07M 4.27B 62.59M 426M 167M 2.16B 168M 165M 7.17B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-08-31 PKR 334.97 -1.12% 344,884
26-08-28 PKR 338.78 -1.35% 240,952
26-08-27 PKR 343.41 +0.17% 322,065
26-08-25 PKR 342.84 +0.54% 596,822
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
334.97PKR
Average target price
510.00PKR
Spread / Average Target
+52.25%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock